Riskpilot← Back to searchSign inGet full accessAbliva AB
ABActiveOrg 5565956538Scheelevägen 2Research and experimental development on natural sciences and engineering · NACE 7210Est. 20005 employees
Revenue 2024
SEK 0
EBITDA margin
—
-3% vs 2023
Equity ratio
84.2%
Financial strength
Net profit 2024
SEK -88,6M
+25% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -88,1M | -3% |
| Net profit | SEK -88,6M | +25% |
| Total assets | SEK 73,1M | -15% |
| Equity | SEK 61,6M | -13% |
| Employees | 5 | — |
Legal name
Abliva AB
Org number
5565956538
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
16 augusti 2000
Share capital
SEK 80 594 000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Firman tecknas av Breidenbach, Alexander Gert Emil Johannes i förening med en av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall direkt eller indirekt genom dotterbolag bedriva forsking, utveckling, försäljning och licensiering av läkemedel samt därmed förenlig verksamhet. Bolaget ska även kunna förvalta fast och lös egendom.
Address
Scheelevägen 2
Phone
+46733919601
Email
info@neurovive.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 5 | 134 | 216 | 151 | 31 | 0 | 137 | 0 |
| Staff expenses | — | — | — | — | — | — | — | — | −0 | — | — |
| EBITDA | −87 535 | −65 542 | −57 773 | −68 589 | −75 032 | −57 852 | −120 652 | −79 709 | 0 | −85 568 | −88 142 |
| Depreciation & amort. | −1 106 | −1 006 | −1 584 | −4 771 | −2 036 | −2 215 | −2 420 | −2 439 | −0 | −10 046 | −1 538 |
| EBIT | −88 641 | −66 548 | −59 357 | −73 360 | −77 068 | −60 067 | −123 072 | −82 148 | 0 | −95 614 | −89 680 |
| Net financials | 502 | −20 570 | 7 248 | −139 | 121 | 105 | — | −2 048 | 0 | −22 624 | 1 106 |
| Profit before tax | −88 139 | −87 118 | −52 109 | −73 490 | −76 947 | −59 961 | −123 072 | −84 196 | 0 | −118 238 | −88 574 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −88 139 | −87 118 | −52 109 | −73 490 | −76 947 | −59 961 | −123 072 | −84 196 | 0 | −118 238 | −88 574 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 194 682 | 183 193 | 143 385 | 115 308 | 171 380 | 173 933 | 82 810 | 206 234 | 0 | 86 314 | 73 137 |
| Equity | 175 751 | 172 222 | 129 143 | 97 001 | 151 406 | 164 009 | 65 098 | 188 228 | 0 | 70 816 | 61 587 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 18 931 | 10 971 | 14 242 | 18 296 | 19 974 | 9 924 | 17 712 | 18 006 | 0 | 15 498 | 11 550 |
| Total debt | 18 931 | 10 971 | 14 242 | 18 296 | 19 974 | 9 924 | 17 712 | 18 006 | 0 | 15 498 | 11 550 |
EBITDA margin
-8814200000.0%
This company
15.8%
Market median
-55786076049% vs market
20152024
Equity ratio
84.2%
This company
38.2%
Market median
+120% vs market
20152024
Return on equity
-143.8%
This company
18.4%
Market median
-882% vs market
20152024
Net profit margin
-8857400000.0%
This company
8.1%
Market median
-109350617384% vs market
20152024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152024
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
EM Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
EO Chief Auditor | Chief Auditor | 2022 | — | — |
EK Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
AC Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
OC Chief Auditor | Chief Auditor | 2022 | — | — |
BM Chief Auditor | Chief Auditor | 2020 | — | — |
MJ Authorized Recipient of Service | Authorized Recipient of Service | 2025 | — | — |
AG Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2025 | — | — | |
| Board of Directors | 2025 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Abliva AB (this company)
Neurovive Pharmaceutical Asia LtdBoard members of Abliva AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Erik Myung-Jin Kinnman | Chief Executive Officer | 0 companies |
| Erik Oskar Wall | Chief Auditor | 0 companies |
| Ellen Kinson Donnelly | Chief Executive Officer | 0 companies |
| Anna Catharina B Janzon Johansson | Chief Executive Officer | 0 companies |
| Ola Christopher Carelius Larsmon | Chief Auditor | 0 companies |
| Bengt Michael Olsson | Chief Auditor | 0 companies |
| Magnus Joakim Hansson | Authorized Recipient of Service | 0 companies |
| Alexander Gert Emil Johannes Breidenbach | Chief Executive Officer | 0 companies |
| Mireille Stefanie Theodore Hélène Sanders | Chairman | 0 companies |
| Anurag Relan | Board of Directors | 0 companies |
| Edwin Moses | Board of Directors | 0 companies |
| David Olof Rikard Bejker | Board of Directors | 0 companies |
| Denise Elaine Goode | Board of Directors | 0 companies |
| Gunnar Magnus Severus Persson | Board of Directors | 0 companies |
| Jan Birger Fredrik Törnell | Board of Directors | 0 companies |
| Roger James Franklin | Board of Directors | 0 companies |
| David Laskow-Pooley | Chairman | 0 companies |